GlobeNewswire·Nov 2, 2026, 4:05 PM ET

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics announced the Compensation Committee granted stock options for 107,600 shares to 4 new employees on October 31, 2026.
The per share exercise price for the inducement stock options is $8.33.
Vesting terms include 25% of shares on the first anniversary of the start date, with the remaining 75% vesting in 36 equal monthly installments thereafter.
All vesting is contingent on the employees' continuing service through the applicable vesting dates.
The awards were granted under the 2025 Inducement Plan adopted on December 24, 2025, in compliance with Nasdaq Listing Rule 5635(c)(4).
The Company's lead candidate aglatimagene completed successful Phase 2a trials in non-small cell lung cancer & pancreatic ductal adenocarcinoma.
A pivotal Phase 3 trial for aglatimagene in localized prostate cancer was conducted under a Special Protocol Assessment with the FDA.
Aglatimagene received FDA Fast Track Designation, Regenerative Medicine Advanced Therapy Designation, & Orphan Drug Designation for specific cancer indications.
The lead HSV platform candidate linoserpaturev is in an ongoing Phase 1b trial for recurrent high-grade glioma.
Linoserpaturev received FDA Fast Track & Orphan Drug Designation, with initial results published in Nature & Science Translational Medicine.
Candel's enLIGHTEN Discovery Platform utilizes HSV-based methods to develop new viral immunotherapies for solid tumors.